Close menu




September 27th, 2022 | 11:45 CEST

Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

  • Biotechnology
Photo credits: pixabay.com

Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: EVOTEC SE INH O.N. | DE0005664809 , DEFENCE THERAPEUTICS INC | CA24463V1013 , FORMYCON AG | DE000A1EWVY8

Table of contents:


    Defence Therapeutics - Groundbreaking results

    Looking purely at the share chart of the Vancouver, Canada-based company, it is difficult to conclude that groundbreaking research successes have been achieved in recent months with the help of the Company's ACCUM technology. The Defence Therapeutics share has dropped by an incredible 78% to CAD 1.61 since it peaked at CAD 8.15 in September last year. The market capitalization amounts to CAD 59.22 million. Currently, the course is working on a bottom formation. Fundamentally, there should be little in the way of a possible increase in the price level.

    The core of the Defence Therapeutics platform is the ACCUM technology, which enables precise transport of vaccine antigens or ADCs in the intact form to target cells with fewer side effects. As a result, improved efficiency and efficacy against many diseases, such as cancer and infections, can be achieved. Market researchers at Emergen Research forecast that the antibody-drug conjugate (ADC) market will reach a total of USD 20.01 billion by 2028, growing at a high rate of 26% per year.

    Recently, the Canadians came up with a breakthrough result to fight lymphoma. Here, the novel vaccine using ACCUM A1-reprogrammed mesenchymal stromal cells was able to cure 80% of the animals with existing lymphomas participating in the study. Here, the platform technology continues to demonstrate positive therapeutic results and application versatility. Through this vaccine technology and ACCUM, Defence Therapeutics can design and develop a variety of vaccine products that can be targeted against multiple solid and hematologic cancer indications after further research. Currently, the Company is actively working on the CMC protocol to produce its A1 MSC vaccine in preparation for a Phase I trial in patients with melanoma.

    Dr Moutih Rafei, VP R&D and Director of Defence Therapeutics, will provide a deeper insight into the business model today at 1:30 pm CEST at the 4th International Investment Forum. Registration for the virtual event is free ii-forum.com.

    Evotec - Order from the highest authority

    The chart performance of the Hamburg-based company in the field of pharmaceutical drug discovery coincides with the price decline of most shares in the biotech sector. After a sharp upswing from the Corona low in March 2020 at EUR 17.17 to a peak of EUR 45.83, the share price is threatening to slip below the low of 2020. A downward breakout is likely to trigger further sell orders. The next prominent support zone would then be the area around EUR 14.70.

    Even an order from the US Department of Defense could not stop the downward run. According to the Company's Hamburg headquarters, the US subsidiary Just-Evotec Biologics is to receive up to EUR 49.9 million for the rapid development of drug prototypes based on monoclonal antibodies against the plague. "It is a clear validation for us of the efficiency and speed we can deliver to our partners through our leading scientific, technological and technical offering," said Craig Johnstone, Evotec's chief operating officer of the US military order.

    Formycon - Encouraging development

    The chart picture of the leading and independent developer of high-quality biopharmaceutical follow-on products, so-called biosimilars, looks much brighter. The share price performance since the Corona low is a whopping 380%. After peaking at EUR 87.90, Formycon shares consolidated at a high level at around EUR 70. An important stop in case of a break of this support zone would be the rising 200-day line at EUR 65.50.

    Also, from the news front, the relative strength is regularly supported by good news flow. Details of a previously unpublished project in the development pipeline have now been announced. FYB206 is a biosimilar candidate for Keytruda (pembrolizumab), which is in an advanced preclinical development phase. In addition to biosimilars in the field of ophthalmology, immunology and two other, as yet unpublished biosimilar candidates, Formycon is expanding its range of indications with FYB206 to include the rapidly growing field of immuno-oncology.

    The active ingredient pembrolizumab is a humanized monoclonal antibody that belongs to the immune checkpoint inhibitors and is used to treat a variety of tumors. It helps the immune system to activate the body's own cellular anti-tumor immune response and kill melanoma cells, for example.

    "Cancer is one of the most common and serious diseases of our time. Effective cancer treatment costs have become a major challenge for global healthcare systems. With the development of the Keytruda biosimilar, we are pursuing the goal of facilitating access to this important drug for patients worldwide, while at the same time providing much needed savings for the healthcare system," commented Dr Stefan Glombitza, CEO of Formycon AG.


    Due to interest rate hikes and further uncertainties regarding rampant inflation, stocks in the capital-intensive biotechnology sector are suffering. However, the sell-off offers a variety of opportunities to participate in promising research projects in the long term. Defence Therapeutics and Formycon were able to report groundbreaking results in cancer research. Evotec repeatedly received the trust of the US government.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Nico Popp on November 30th, 2022 | 13:33 CET

    Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

    • Biotechnology
    • Covid19
    • Cancer

    Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

    New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

    • Mining
    • Commodities
    • Biotechnology
    • chemicals

    As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

    Read